Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry.
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2016
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms EVHALAVEN
- Sponsors Eisai Co Ltd
- 11 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2015 According to an Eisai media release, data from this study will be presented at the 18th Biennial Congress of European Cancer Congress (ECC).
- 18 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.